• 1
    DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 5th edition. Philadelphia: Lippincott-Raven, 1997.
  • 2
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 3528.
  • 3
    Khayat D, Gil-Delgado M, Antoine EC, Nizri D, Bastian G. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Oncology (Huntingt) 2001; 15: 41529.
  • 4
    Vanhoefer U, Harstrick A, Achterrath W, Cao S, Seeber S, Rustum YM. Irinotecan in the treatment of colorectal cancer: clinical overview. J Clin Oncol 2001; 19: 150118.
  • 5
    Vanhoefer U, Wilke H. Oral fluoropyrimidine-based combination therapy in gastrointestinal cancer. Oncology (Huntingt) 2001; 15(Suppl 2): 7984.
  • 6
    Lorenz M, Muller HH, Staib-Sebler E, Vetter G, Gog C, Petrowsky H, et al. Relevance of neoadjuvant and adjuvant treatment for patients with resectable liver metastases of colorectal carcinoma. Langenbecks Arch Surg 1999; 384: 32838.
  • 7
    Riethmüller G, Schneider-Gädicke E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. The German Cancer Aid 17-1A Study Group: randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet 1994; 343: 117783.
  • 8
    Riethmüller G, Holz E, Schlimok G, Schmiegel W, Raab R, Höffken K, et al. Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998; 16: 178894.
  • 9
    Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY, et al. A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data. Cancer Immunol Immunother 1990; 32: 18590.
  • 10
    Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review “Of Mice and Men.” Hybridoma 1997; 16: 1017.
  • 11
    Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 263948.
  • 12
    Colombat P, Salles G, Brousse N, Eftekhari P, Soubeyran P, Delwail V, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001; 97: 1016.
  • 13
    Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 45965.
  • 14
    Press OW, Eary JF, Appelbaum PJ, Nelp WB, Glenn S, Fisher DR, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphoma. Lancet 1995; 346: 33640.
  • 15
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Siegel JA, Goldenberg DM. Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and anti-mucin monoclonal antibodies. J Nucl Med 1997; 38: 40918.
  • 16
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an iodine-131–labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 1997; 38: 85870.
  • 17
    Behr TM, Salib AL, Liersch T, Behe M, Angerstein C, Blumenthal RD, et al. Radioimmunotherapy of small volume disease of colorectal cancer metastatic to the liver: preclinical evaluation in comparison to standard chemotherapy and initial results of a phase I clinical study. Clin Cancer Res 1999; 5: 3232s3242s.
  • 18
    Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71: 347885.
  • 19
    Sharkey RM, Juweid M, Shevitz J, Behr T, Dunn R, Swayne LC, et al. Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies. Cancer Res 1995; 55: 593545.
  • 20
    Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983; 43: 68692.
  • 21
    Behr TM, Juweid ME, Sharkey RM, Dunn RM, Ying Z, Becker WS, et al. Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies. Nucl Med Commun 1996; 17: 76780.
  • 22
    Behr TM, Dunn RM, Gratz S, Weber E, Herrmann A, Becker W. An automated scheme for internal radiation dosimetry in nuclear therapy: gamma- or bremsstrahlung-based dose calculation in the therapy of differentiated thyroid cancer, radiosynoviorthesis, bone pain palliation and radioimmuno-therapy. J Nucl Med 1997; 38: 225P.
  • 23
    Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 53846.
  • 24
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Siegel JA, et al. Hematologic toxicity in the radioimmunotherapy of solid cancers with 131I-labeled anti-CEA NP-4 IgG1: dependence on red marrow dosimetry and pretreatment. Proceedings of the Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, TN, 1996;1: 11326.
  • 25
    Ardalan B, Chua L, Tian EM, Reddy R, Sridhar K, Benedetto P, et al. A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 1991;9: 62530.
  • 26
    Blumenthal RD, Sharkey RM, Natale AM, Kashi R, Wong G, Goldenberg DM. Comparison of equitoxic radioimmunotherapy and chemotherapy in the treatment of human colonic cancer xenografts. Cancer Res 1994; 54: 14251.
  • 27
    Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, et al. Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 131I-labeled monoclonal antibodies. Cancer Res 1992; 52: 603644.
  • 28
    Behr TM, Blumenthal RD, Memtsoudis S, Sharkey RM, Gratz S, Becker W, et al. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 2000; 6: 49007.
  • 29
    Behr TM, Memtsoudis S, Vougioukas V, Liersch T, Gratz S, Schmidt F, et al. Radioimmunotherapy of colorectal cancer in small volume disease and in an adjuvant setting: preclinical evaluation in comparison to equitoxic chemotherapy and initial results of an ongoing phase-I/II clinical trial. Anticancer Res 1999; 19: 242732.
  • 30
    Machover D. A comprehensive review of 5-fluorouracil and leucovorin in patients with metastatic colorectal carcinoma. Cancer 1997; 80: 117987.
  • 31
    Tschmelitsch J, Barendswaard E, Williams C Jr., Yao TJ, Cohen AM, Old LJ, et al. Enhanced antitumor activity of combination radioimmunotherapy (131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 1997;57: 21816.